Digestive Diseases and Sciences

, Volume 50, Issue 3, pp 547–551

Impact of Immunosuppressive Treatment on Liver Fibrosis in Autoimmune Hepatitis

  • Mehdi Mohamadnejad
  • Reza Malekzadeh
  • Siavosh Nasseri-Moghaddam
  • Sepideh Hagh-Azali
  • Nasser Rakhshani
  • Seyed Mohamad Tavangar
  • Mojtaba Sedaghat
  • Seyed Meysam Alimohamadi
Article

DOI: 10.1007/s10620-005-2472-5

Cite this article as:
Mohamadnejad, M., Malekzadeh, R., Nasseri-Moghaddam, S. et al. Dig Dis Sci (2005) 50: 547. doi:10.1007/s10620-005-2472-5

Abstract

The impact of treatment on progression of fibrosis in autoimmune hepatitis (AIH) is unknown. We assessed the changes in liver fibrosis before and after treatment among these patients. Nineteen AIH patients who had paired liver biopsies were studied. Of these, seven had been treated with 6 months of cyclosporine A and the rest with 6 months of prednisolone for induction of remission. Thereafter all had been maintained on azathioprine. Biopsy specimens before and after treatment were reviewed by one pathologist and scored by the Ishak method. Mean fibrosis stages before and after treatment were compared. Also, factors predicting significant fibrosis (stage ≥3) and cirrhosis (stage ≥5) at presentation were assessed. Mean interval between biopsies was 3.38 years. Mean fibrosis stage decreased from 4.53 to 2.16 following treatment (P < 0.001). Mean decrement in inflammatory grade was 8 scores (range, 4–10) in patients in whom fibrosis improved, and 2 scores (range, 0–4) in patients in whom fibrosis did not decrease after treatment (P < 0.001). ALT-to-platelet ratio was the best predictor of significant fibrosis and also cirrhosis. Fibrosis commonly improves after immunosuppressive treatment in AIH. ALT-to-platelet ratio can predict accurately the presence of significant fibrosis and cirrhosis in AIH.

Keywords:

autoimmune hepatitis liver fibrosis therapeutics immunosuppressive agents. 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Mehdi Mohamadnejad
    • 1
    • 2
  • Reza Malekzadeh
    • 2
    • 4
  • Siavosh Nasseri-Moghaddam
    • 2
  • Sepideh Hagh-Azali
    • 2
  • Nasser Rakhshani
    • 2
  • Seyed Mohamad Tavangar
    • 2
  • Mojtaba Sedaghat
    • 3
  • Seyed Meysam Alimohamadi
    • 2
  1. 1.Gastrointestinal and Liver Disease Research CenterIran University of Medical SciencesTehranIran
  2. 2.Digestive Disease Research CenterTehranIran
  3. 3.Department of Community Medicine, School of MedicineTehran University of Medical SciencesTehranIran
  4. 4.Digestive Disease Research CenterTehran University of Medical SciencesTehranIran

Personalised recommendations